1Reese AB. Tumor of the eye [M]. Hagerstwon, Maryland. USA:Harper&Row publishers Inc, 1976,250-254.
2Seregard S. Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma [J]. J Clin Pathal, 1996,49:338-342.
3Sharara NA, Alexander RA, Luthert PJ, et al. Differential immunoreactivity of melanotic lesions of the conjunctiva [J].Histopathology, 2001,39:426-431.
4Folberg R, McLean IW, Zimmerman LE. Conjunctival melanosis of melanoma [J]. Ophthalmology, 1984,91:673.
5Shields CL, Shields JA, Gunduz K, et al. Conjunctiva melanoma:risk factors for recurrence, exenteration, metastasis and death in 150 consecutive patients [J]. Arch Ophthalmol, 2000,118:1497-1507.
6Helgaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea:comparision of the novel antibody against melan-A with S-100protein and HMB-45 [J]. Melanoma Res, 2000,10:350-354.
7Iwamoto S, Burrows RC, Grossniklaus HE, et al. Immunophenotype of conjunctival melanomas: comparisions with uveal and cutaneous melanomas [J]. Arch Ophthalmol, 2002, 120:1625-1629.
9Shields CL, Shields JA, Armtrony T. Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy [J]. Am J Ophthalmol, 2001,132:576-578.
10Demirci H, Meconnick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations [J]. Arch Ophthalmol, 2000,118: 885-891.
